Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151123 | 0.72 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL10477477 | 0.72 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| Lithium Ion SCHEMBL6628951 | 0.72 | NOTUM (0.63) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL23902687 | 0.71 | NOTUM (0.58) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL5354348 | 0.71 | NOTUM (0.68) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL29453277 | 0.71 | TSHR (0.69) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL931955 | 0.71 | TSHR (0.69) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL30522768 | 0.71 | CDK4 (0.43) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL4080987 | 0.71 | CDK4 (0.43) | NOTUMTSHRRAB9AL3MBTL1KMT2A | |
| SCHEMBL10646439 | 0.70 | TSHR (0.62) | NOTUMTSHRRAB9AL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912707-B2 | Mitragynine alkaloids as opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210179618-A1 | MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-17 | — | — | US | disclosed |
| US-10961244-B2 | Mitragynine alkaloids as opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190084983-A1 | MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017165738-A1 | MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-1404317-B1 | 5-HALO-TRYPTAMINE DERIVATIVES USED AS LIGANDS OF THE 5-HT 6? AND/OR 5-HT 7? SEROTONIN RECEPTORS | SIGMA TAU IND FARMACEUTI (IT) | 2008-12-10 | — | — | EP | disclosed |
| US-7098233-B2 | 5-halo-tryptamine derivatives used as ligands on the 5-HT6 and/or 5-HT7 serotonin receptors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-08-29 | — | — | US | disclosed |
| US-20040235899-A1 | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1404317-A1 | 5-HALO-TRYPTAMINE DERIVATIVES USED AS LIGANDS OF THE 5-HT 6? AND/OR 5-HT 7? SEROTONIN RECEPTORS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000252-A1 | 5-HALO-TRYPTAMINE DERIVATIVES USED AS LIGANDS OF THE 5-HT6 AND/OR 5-HT7 SEROTONIN RECEPTORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-01-03 | — | — | WO | disclosed |
| US-5480983-A | ANALGESICS, HYPOTENSIVE AGENTS | LABORATOIRES UPSA (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5229505-A | CNS and cardiovascular effects | LABORATOIRES UPSA (FR) | 1993-07-20 | — | — | US | disclosed |
| US-4252803-A | HYPOTENSIVE AGENTS, ANALGESICS | GLAXO GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
| US-4087444-A | Amides as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235899-A1 | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | HTR7, HTR6, HTR1A | NOTUM 937/4885TSHR 132/4885RAB9A 2223/4885 |
| US-20210179618-A1 | MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRM1, OPRD1 | NOTUM 2998/4885TSHR 637/4885RAB9A 168/4885 |
| US-11912707-B2 | Mitragynine alkaloids as opioid receptor modulators | OPRK1, OPRM1, OPRD1 | NOTUM 2998/4885TSHR 637/4885RAB9A 168/4885 |
| US-20190084983-A1 | MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRM1, OPRD1 | NOTUM 2998/4885TSHR 637/4885RAB9A 168/4885 |
| US-10961244-B2 | Mitragynine alkaloids as opioid receptor modulators | OPRK1, OPRM1, OPRD1 | NOTUM 2998/4885TSHR 637/4885RAB9A 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.